A fixed 15.5% manufacturer rebate on patented branded drugs replaces a proposed variable, expenditure-linked mechanism after coordinated industry pressure and threats to curtail German investment and ...

Pairing Tennr referral intake and documentation automation with TailorMed affordability tooling is designed to surface access barriers earlier and shorten time-to-therapy for infusion and specialty ...

Section 232 introduces a staged tariff regime: 100% default for patented drugs/APIs/KSMs, reduced 20% with approved onshoring plans, and temporary 0% if paired with MFN pricing until 2029. Deadlines ...

Deanna Horner, EVP of Enterprise DIRECT Strategy at EVERSANA, explains which therapeutic areas will lead DTP adoption and her five-year outlook for the model. Direct-to-patient (DTP) programs are no ...

CMS-driven price relief may expand access, but adherence is the key determinant of durable cardiometabolic and weight outcomes in chronic-disease management. Discontinuation rates are high: roughly ...

PBM reform scrutiny of reimbursement, rebate flow, and compensation can shift benefit conditions that determine how manufacturer-funded copay, buy-down, and support programs function at dispensing.

Clinician-led engagement outperforms non-clinical call-center models, with “nurse ambassador” programs enabling escalation, symptom recognition, and disease-specific education that supports safer, ...

Bansi Nagji discusses the shifting science behind rare and orphan drug development, including what it takes for therapies to succeed well beyond launch. Bansi Nagji, CEO of PANTHERx Rare, explores how ...

Dual BAFF/APRIL blockade targets upstream B-cell survival signaling to reduce production of galactose-deficient IgA1 and anti–Gd-IgA1 autoantibodies driving nephritogenic immune complexes. ORIGIN 3 ...